ACN Newswire
SHANGHAI, Nov 30, 2024 – (ACN Newswire) – Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) was conducted in the United States in 40 subjects with Type 2 diabetes (T2D…
Read More
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
Clora Motsinger
02:26
SHANGHAI, Nov 30, 2024 – (ACN Newswire) – Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA
